Table of Contents PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 05: MARKET SIZING • Market definition • Market sizing 2017 • Market size and forecast PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: CUSTOMER LANDSCAPE PART 08: MARKET SEGMENTATION BY END-USER • Overview • Comparison by end-user • Pharmaceutical and biotechnology companies • Academic institutes and research laboratories • Others • Market opportunity by end-user PART 09: REGIONAL LANDSCAPE • Overview • Regional comparison • Americas • EMEA • APAC • Market opportunity PART 10: DECISION FRAMEWORK PART 11: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 12: MARKET TRENDS • Growing awareness of microbiome in cancer development and therapy • Growing demand for highly accurate forensic tools • Increasing adoption of microbiome sequencing in clinical workflows PART 13: VENDOR LANDSCAPE • Overview • Landscape disruption PART 14: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • BGI • Clinical-Microbiomics • Diversigen • GATC Biotech • Second Genome • Other prominent vendors PART 15: APPENDIX • List of abbreviations List of Exhibits Exhibit 01: Related market Exhibit 02: Market characteristics Exhibit 03: Market segments Exhibit 04: Market definition - Inclusions and exclusions checklist Exhibit 05: Market size 2017 Exhibit 06: Validation techniques employed for market sizing 2017 Exhibit 07: Global microbiome sequencing services market – Market size and forecast 2017-2022 ($ mn) Exhibit 08: Global microbiome sequencing services market – Year over year growth 2018-2022 (%) Exhibit 09: Five forces analysis 2017 Exhibit 10: Five forces analysis 2022 Exhibit 11: Bargaining power of buyers Exhibit 12: Bargaining power of suppliers Exhibit 13: Threat of new entrants Exhibit 14: Threat of substitutes Exhibit 15: Threat of rivalry Exhibit 16: Market condition - Five forces 2017 Exhibit 17: Market condition: Five forces 2022 Exhibit 18: Customer landscape Exhibit 19: End-user – Market share 2017-2022 (%) Exhibit 20: Comparison by end-user Exhibit 21: Pharmaceutical and biotechnology companies – Market size and forecast 2017-2022 ($ mn) Exhibit 22: Pharmaceutical and biotechnology companies – Year over year growth 2018-2022 (%) Exhibit 23: Academic institutes and research laboratories – Market size and forecast 2017-2022 ($ mn) Exhibit 24: Academic institutes and research laboratories – Year over year growth 2018-2022 (%) Exhibit 25: Others – Market size and forecast 2017-2022 ($ mn) Exhibit 26: Others – Year over year growth 2018-2022 (%) Exhibit 27: Market opportunity by end-user Exhibit 28: Global – Market share by geography 2017-2022 (%) Exhibit 29: Regional comparison Exhibit 30: Americas – Market size and forecast 2017-2022 ($ mn) Exhibit 31: Americas – Year over year growth 2018-2022 (%) Exhibit 32: Top 3 countries in Americas Exhibit 33: EMEA – Market size and forecast 2017-2022 ($ mn) Exhibit 34: EMEA – Year over year growth 2018-2022 (%) Exhibit 35: Top 3 countries in EMEA Exhibit 36: APAC – Market size and forecast 2017-2022 ($ mn) Exhibit 37: APAC – Year over year growth 2018-2022 (%) Exhibit 38: Top 3 countries in APAC Exhibit 39: Market opportunity Exhibit 40: R&D funding in $ millions for malaria from 2013-2016 Exhibit 41: R&D funding in $ millions for HIV from 2013-2016 Exhibit 42: Cost of sequencing per genome in $ (2001-2015) Exhibit 43: Vendor landscape Exhibit 44: Landscape disruption Exhibit 45: Vendors covered Exhibit 46: Vendor classification Exhibit 47: Market positioning of vendors Exhibit 48: BGI: Overview Exhibit 49: BGI: Business segments Exhibit 50: BGI: Organizational developments Exhibit 51: BGI: Geographic focus Exhibit 52: BGI: Segment focus Exhibit 53: BGI: Key offerings Exhibit 54: Clinical-Microbiomics: Overview Exhibit 55: Clinical-Microbiomics: Business segments Exhibit 56: Clinical-Microbiomics: Organizational developments Exhibit 58: Clinical-Microbiomics: Geographic focus Exhibit 59: Clinical-Microbiomics: Segment focus Exhibit 60: Clinical-Microbiomics: Key offerings Exhibit 61: Diversigen: Overview Exhibit 62: Diversigen – Business segments Exhibit 63: Diversigen – Organizational developments Exhibit 64: Diversigen – Geographic focus Exhibit 65: Diversigen – Segment focus Exhibit 66: Diversigen – Key offerings Exhibit 67: GATC Biotech: Overview Exhibit 68: GATC Biotech: Business segments Exhibit 69: GATC Biotech: Organizational developments Exhibit 70: GATC Biotech: Geographic focus Exhibit 71: GATC Biotech: Segment focus Exhibit 72: GATC Biotech – Key offerings Exhibit 73: Second Genome: Overview Exhibit 74: Second Genome – Business segments Exhibit 75: Second Genome – Organizational developments Exhibit 76: Second Genome – Geographic focus Exhibit 77: Second Genome – Segment focus Exhibit 78: Second Genome – Key offering

BGI, Clinical-Microbiomics, Diversigen, GATC Biotech, and Second Genome.